Madrigal Pharmaceuticals shares are trading higher after UBS maintained a Buy rating on the stock and raised its price target from $411 to $441.
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals shares rose following UBS's decision to maintain a Buy rating and increase the price target from $411 to $441.
November 01, 2024 | 7:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has maintained a Buy rating on Madrigal Pharmaceuticals and increased its price target from $411 to $441, leading to a rise in the company's stock price.
The increase in price target by UBS, a reputable financial institution, suggests positive future prospects for Madrigal Pharmaceuticals, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100